AU2018253962B2 - Coversin for the treatment of autoimmune blistering diseases - Google Patents

Coversin for the treatment of autoimmune blistering diseases Download PDF

Info

Publication number
AU2018253962B2
AU2018253962B2 AU2018253962A AU2018253962A AU2018253962B2 AU 2018253962 B2 AU2018253962 B2 AU 2018253962B2 AU 2018253962 A AU2018253962 A AU 2018253962A AU 2018253962 A AU2018253962 A AU 2018253962A AU 2018253962 B2 AU2018253962 B2 AU 2018253962B2
Authority
AU
Australia
Prior art keywords
ala
sequence
asp
seq
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018253962A
Other languages
English (en)
Other versions
AU2018253962A1 (en
Inventor
Brihad ABHYANKAR
Miles Andrew Nunn
Christian David SADIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volution Immuno Pharmaceuticals SA
Original Assignee
Volution Immuno Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1706406.4A external-priority patent/GB201706406D0/en
Priority claimed from GBGB1706404.9A external-priority patent/GB201706404D0/en
Priority claimed from GBGB1706452.8A external-priority patent/GB201706452D0/en
Application filed by Volution Immuno Pharmaceuticals SA filed Critical Volution Immuno Pharmaceuticals SA
Publication of AU2018253962A1 publication Critical patent/AU2018253962A1/en
Application granted granted Critical
Publication of AU2018253962B2 publication Critical patent/AU2018253962B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018253962A 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases Active AU2018253962B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1706406.4A GB201706406D0 (en) 2017-04-21 2017-04-21 Method of treatment
GBGB1706404.9A GB201706404D0 (en) 2017-04-21 2017-04-21 Method of treatment
GB1706404.9 2017-04-21
GB1706406.4 2017-04-21
GB1706452.8 2017-04-24
GBGB1706452.8A GB201706452D0 (en) 2017-04-24 2017-04-24 Method of treatment
PCT/EP2018/060241 WO2018193122A1 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Publications (2)

Publication Number Publication Date
AU2018253962A1 AU2018253962A1 (en) 2019-10-31
AU2018253962B2 true AU2018253962B2 (en) 2024-12-05

Family

ID=62235916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018253962A Active AU2018253962B2 (en) 2017-04-21 2018-04-20 Coversin for the treatment of autoimmune blistering diseases

Country Status (12)

Country Link
US (2) US11730792B2 (enExample)
EP (2) EP4275696A1 (enExample)
JP (2) JP7209637B2 (enExample)
KR (1) KR102656199B1 (enExample)
CN (1) CN110896606B (enExample)
AU (1) AU2018253962B2 (enExample)
CA (1) CA3059657A1 (enExample)
DK (1) DK3612208T5 (enExample)
ES (1) ES2945433T3 (enExample)
IL (1) IL269895B2 (enExample)
PL (1) PL3612208T3 (enExample)
WO (1) WO2018193122A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612206A1 (en) * 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
AU2019468121A1 (en) 2019-09-27 2022-05-12 Volution Immuno Pharmaceuticals Sa Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
MXPA05012880A (es) 2003-06-02 2006-02-22 Evolutec Ltd Inhibidores de complemento.
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
WO2007095230A2 (en) 2006-02-13 2007-08-23 The Trustees Of The University Of Pennsylvania TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY
JP2010502687A (ja) 2006-09-08 2010-01-28 ヴァーレイ・リミテッド 呼吸器疾患の治療方法
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EA200901211A1 (ru) 2007-03-22 2010-04-30 Новартис Аг Антигены белка с5 и их применение
PL2173890T3 (pl) * 2007-06-21 2011-07-29 Univ Muenchen Tech Białka czynne biologicznie o zwiększonej stabilności in vivo i (lub) in vitro
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2011056972A2 (en) * 2009-11-04 2011-05-12 Case Western Reserve University Compositions and methods of treating a t cell mediated disorder
MX2011003328A (es) * 2008-10-06 2011-06-20 Carolus Therapeutics Inc Metodos para tratar inflamacion.
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CN102762223B (zh) 2010-01-08 2014-09-03 沃卢申伊谬诺制药公司 用于治疗呼吸道病毒性感染的ev576
ES3044832T3 (en) 2011-06-22 2025-11-27 Apellis Pharmaceuticals Inc Methods of treating chronic disorders with complement inhibitors
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分ｃ５拮抗劑之篩選分析
US20160051673A1 (en) * 2013-03-29 2016-02-25 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
WO2016094834A2 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. A method for treating a complement mediated disorder caused by an infectious agent in a patient
US9937222B2 (en) * 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
US11840564B2 (en) 2015-06-09 2023-12-12 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
EP3307316A1 (en) * 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP4462121A3 (en) 2015-09-11 2025-01-22 Alexion Pharmaceuticals, Inc. Recombinant glycosylated eculizumab and eculizumab variants
GB201706406D0 (en) 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
EP3612206A1 (en) 2017-04-21 2020-02-26 Volution Immuno Pharmaceuticals SA Coversin for the treatment of cicatrising eye inflammatory disorders
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Also Published As

Publication number Publication date
ES2945433T3 (es) 2023-07-03
JP2023040169A (ja) 2023-03-22
KR102656199B1 (ko) 2024-04-09
EP4275696A1 (en) 2023-11-15
US11730792B2 (en) 2023-08-22
IL269895B2 (en) 2024-06-01
JP7600278B2 (ja) 2024-12-16
CN110896606A (zh) 2020-03-20
US20240009270A1 (en) 2024-01-11
IL269895B1 (en) 2024-02-01
JP2020517627A (ja) 2020-06-18
DK3612208T5 (da) 2024-09-02
JP7209637B2 (ja) 2023-01-20
IL269895A (enExample) 2019-12-31
DK3612208T3 (da) 2023-05-08
WO2018193122A1 (en) 2018-10-25
KR20190139233A (ko) 2019-12-17
US20200113971A1 (en) 2020-04-16
EP3612208A1 (en) 2020-02-26
PL3612208T3 (pl) 2023-07-24
AU2018253962A1 (en) 2019-10-31
CA3059657A1 (en) 2018-10-25
CN110896606B (zh) 2024-07-16
EP3612208B1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
US20240009270A1 (en) Coversin for the treatment of autoimmune blistering diseases
AU2015270396B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
JP7153669B2 (ja) 瘢痕性眼炎症障害の治療のためのコバーシン
EP3612207B1 (en) Coversin variants lacking c5 binding
US20250195612A1 (en) Coversin for use in the treatment of rheumatic diseases
AU2019468121A1 (en) Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA)
KR20220018963A (ko) 치료 방법
JP7511551B2 (ja) 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法
NZ727053B2 (en) Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)